Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Lytix Biopharma.

    Client Virtual Booth

    LYTIX BIOPHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Lytix Biopharma
    Norway Flag
    Country
    Country
    Norway
    Address
    Address
    Lytix Biopharma AS Hoffsveien 4, 0275 Oslo
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lytixbiopharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lytix-biopharma/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lytix Biopharma AS Announces that an Abstract on LTX-315 in Combination With Adoptive Cell Therapy Is Selected for a Poster Presentation at ASCO 2022

    Details:

    The trial demonstrated that combination of LTX-315 and ACT is feasible and tolerable, and that CD4+ and CD8+ T cells can be expanded in vitro from STS that have been pretreated with the oncolytic molecule LTX-315.


    Lead Product(s): Ruxotemitide,Adoptive Cell Therapy

    Therapeutic Area: Oncology Product Name: LTX-315

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 27, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lytix Biopharma to Present at the American Society of Clinical Oncology (ASCO) Annual Meeting

    Details:

    LTX-315 is a potential first-in-class oncolytic molecule administered directly into a tumor to induce immunogenic cell death, which also has demonstrated positive tumor-specific immune cell responses in multi-indication Phase I/II oncology trials.


    Lead Product(s): Ruxotemitide,Tumour Infiltrating Lymphocytes

    Therapeutic Area: Oncology Product Name: LTX-315

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 28, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lytix Biopharma Receives Milestone Payment From Verrica Pharmaceuticals Inc. Triggered by First Patient Dosed With LTX-315

    Details:

    Verrica, has an exclusive license agreement with Lytix to develop and commercialize LTX-315 for skin cancer conditions. LTX-315 is a first-in-class oncolytic peptide derived from human lactoferrin, with potential lytic and immunostimulating activities.


    Lead Product(s): Ruxotemitide

    Therapeutic Area: Oncology Product Name: LTX-315

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Verrica Pharmaceuticals

    Deal Size: $111.0 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement April 05, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Verrica Pharmaceuticals Licenses LTX-315 from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications

    Details:

    The licensing agreement is focused on developing and commercializing LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development.


    Lead Product(s): Ruxotemitide

    Therapeutic Area: Oncology Product Name: LTX-315

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Verrica Pharmaceuticals

    Deal Size: $113.5 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement August 11, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search